ABSTRACT Pyrazinamide (PZA) is a prodrug that is converted to pyrazinoic acid by the enzyme pyrazinamidase, encoded by the pncA gene in Mycobacterium tuberculosis. Molecular identification of mutations in pncA offers the potential for rapid detection of pyrazinamide resistance (PZA r ). However, the genetic variants are highly variable and scattered over the full length of pncA, complicating the development of a molecular test. We performed a large multicenter study assessing pncA sequence variations in 1,950 clinical isolates, including 1,142 multidrug-resistant (MDR) strains and 483 fully susceptible strains. The results of pncA sequencing were correlated with phenotype, enzymatic activity, and structural and phylogenetic data. We identified 280 genetic variants which were divided into four classes: (i) very high confidence resistance mutations that were found only in PZA r strains (85%), (ii) high-confidence resistance mutations found in more than 70% of PZA r strains, (iii) mutations with an unclear role found in less than 70% of PZA r strains, and (iv) mutations not associated with phenotypic resistance (10%). Any future molecular diagnostic assay should be able to target and identify at least the very high and high-confidence genetic variant markers of PZA r ; the diagnostic accuracy of such an assay would be in the range of 89.5 to 98.8%.
phenotypic tests (7) . The difficulties with culture-based PZA susceptibility testing result from several factors, including suboptimal test media with unreliable pH and larger inocula that reduce the activity of PZA (8, 9) . Furthermore, the critical concentration itself may result in inconsistent results for isolates with a PZA MIC close to this concentration (10) . While for isoniazid and rifampin, highly reliable culture-based drug susceptibility testing (DST) techniques and rapid molecular assays such as the line probe assay MTBDRplus (Hain Lifescience GmbH, Nehren, Germany) and the cartridge-based Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) are available (11) , no commercial molecular assays are currently marketed for PZA.
Great efforts have been made in understanding molecular resistance mechanisms. PZA is a prodrug that needs to be converted to an active compound, pyrazinoic acid, by the bacterial pyrazinamidase (PZase) (encoded by pncA). Mutations/variations in pncA leading to the loss of PZase activity are the major mechanism leading to PZA resistance (PZA r ) (4, 12) . However, while high numbers of PZA r cases can be related to inactivation of the PZase, the genetic variants, including single nucleotide polymorphisms (SNPs) and small deletions, are highly diverse and scattered over the full length of the 561 bp of the pncA gene (4, 12) . This complicates the development of molecular tests, as no "hot spot region" comprising the majority of mutations is present in the pncA gene, as is present in rpoB for rifampin resistance.
Accordingly, future molecular approaches to detect PZA r in clinical isolates need to cover at least a significant number of possible variants, if not the complete gene, to reach a high sensitivity (e.g., using approaches based on classical Sanger sequencing or next-generation genome sequencing). These techniques must be combined with an appropriate interpretation algorithm/database that distinguishes SNPs clearly associated with drug resistance from those for which the impact for developing PZA r is unclear, e.g., due to phylogenic variants found in members of the MTBC (13, 14) . In-depth knowledge of the variants found in PZA r strains combined with evidence-based correlation with resistance phenotypes are needed to develop large-scale databases ensuring valid data interpretation. The fact that such a valid data basis is currently lacking represents a substantial limitation for molecular PZA DST.
To tackle this question, we performed a large multicenter study assessing pncA sequence variations in 1,950 MTBC pansusceptible strains and PZA r strains. The strains were classified in phylogenetic lineages to identify variants that are phylogenetically informative but not likely to be involved in PZA r and those that are occurring in strains from different groups and are obviously under positive selection. Using this comprehensive approach, we could catalog 239 high-confidence PZA r mutations and a number of pncA variants most likely not involved in PZA r .
RESULTS
We studied 1,950 clinical isolates, including 1,142 MDR strains and 483 fully susceptible strains (see Table S1 in the supplemental material). By phenotypic DST, 1,107 clinical isolates were susceptible to PZA, whereas 843 were classified as PZA r . Genotyping data were available for 1,853 isolates (95.0%). Predominant lineages among the strains investigated were Beijing (47.8%), LAM (9.0%), Ural (7.7%), and Haarlem (5.0%). Other lineages found (Ghana, EAI, Delhi/CAS, H37Rv_like, Uganda I and II, West African 1 and 2, S, Cameroon, Sierra Leone 1 and 2, Mycobacterium bovis, H37Rv, UZB_H37Rv_like, New-1, X, CAS, TUR,and Mycobacterium microti vole) each represented less than 5% of isolates (Fig. 1) . Six percent were classified as EuroAmerican strains not belonging to a valid lineage described previously ("other undefined," as described in reference 15), and 5.2% of strains were classified as "unknown," because it was not possible to assign a defined lineage.
Considering the sequencing results, 1,062 (54.5%) isolates were found to be wild type (WT) for the pncA gene, whereas 888 harbored variations in the pncA gene that amounted to a total of 280 genetic variants comprising 67 insertions or deletions (indels) and 213 SNPs (see Table S2 in the supplemental material). The PZase enzymatic activity was available for 251 clinical isolates accounting for 90 different genetic variants. Considering the distribution of the mutations across the entire gene, 73 (39.0%) codons were not affected by mutations, whereas the remaining 114 codons presented one or more mutations (Fig. 2) . Only 50 codons showed a frequency of mutation over the mean value of 0.5%, but despite this, a clear hot spot region could not be found; the most frequently affected regions (representing more than 70% of mutated strains) were found at the promoter (positions Ϫ13 to Ϫ3) and at codons 6 to 15, 50 to 70, 90 to 100, 130 to 145, and 170 to 175 (Fig. 3) .
For mutations found in both PZA-sensitive (PZA s ) and PZA r isolates, enzymatic activity and structural analysis results were used to adjust for possible errors in phenotypic DST whenever possible and to obtain a "revised DST" (included as "DST rev" in Table S1 in the supplemental material). Accordingly, 56 clinical isolates originally reported as PZA s were reclassified as PZA r (Table S1). The final distribution of mutations among revised PZA s and PZA r isolates is summarized in Table 1 . To further validate the classification data, we analyzed the homoplastic occurrence of particular mutations (e.g., the emergence in strains of two phylogenetic lineages [16] ). As the homoplasy level is rather low in MTBC genomes, this confirms that these mutations are most likely under positive selection and involved in the development of PZA r . Using this procedure, four classes of genetic variants were identified: (i) very high confidence resistance mutations that were found only in PZA r strains (category A), (ii) high-confidence resistance mutations found in more than 70% of PZA r strains (category E), (iii) mutations with an unclear role found in less than 70% in PZA r strains (category D), and (iv) genetic variants (including the wild type) not involved in phenotypic resistance (category B). Table S2 in the supplemental material summarizes these clinically relevant categories; a graphical overview is provided in Fig. 4 . Table S2 in the supplemental material). Several mutations affect the catalytic residues and amino acids recruited in the scaffold of the active site or directly/indirectly involved in the coordination of the Fe 2ϩ ion (Asp8Gly/Ala/Glu/ Asn, His51Gln/Tyr, His71Arg, Asp49Glu/Asn/Ala, His57Arg/Tyr/ Gln/Pro, Trp68Arg/Gly/Cys/Stop/Leu, Gln10Pro/Arg, and His137Pro/Arg/Asp) or residues engaged in the hydrophobic core (Ile6Thr, Val44Gly, Val139Gly/Leu, Met175Thr/Val, and Phe94Cys/Ser/Leu). Out of the 90 variants tested, 87 variants, including nucleotide substitutions at position Ϫ11, were also associated with negative PZase activity, and 55 genetic variants (detected in 332 isolates) were found in strains of at least 2 different lineages, indicating homoplasy (data not shown). Table 2 reports the mutations mapping in the most frequently affected regions. 
Mutations

FIG 4 Distribution of genetic variants across the four categories identified: (i) very high confidence resistance mutations, (ii) high-confidence resistance
mutations, (iii) mutations with an unclear role, and (iv) mutations not involved in phenotypic resistance. The number of isolates belonging to each category is also reported. The inner ring shows the percentages of mutations affecting the structure of the enzyme for each category of genetic variants. PZA-R, PZA resistance. *, including wild-type isolates for the pncA gene. a A-11C, nucleotide change A to C in position Ϫ11; Del-5 ¡ G, deletion of nucleotide G in position Ϫ5; ATC6AAC, ATC at codon 7 changed to AAC; WT ϩ GTC7GGC, double pattern wild-type ϩ GTC at codon 7 changed to GGC; Ins37 ¡ GACT, GACT inserted at codon 37. b Promoter Ϫ11, nucleotidic mutation affecting the promoter region at position Ϫ11; del, deletion; FSC, frameshift codon; ins, insertion. c p.S, probability associated with the susceptible phenotype. d p.R, probability associated with the resistant phenotype.
Mutations conferring PZA r at high confidence. Nine genetic variants (32 strains, category E) were found in both PZA r and PZA s isolates, but with a proportion higher than 70% in PZA r strains. These mutations were mainly associated with an increase in free energy and/or structural constraints and were most frequently associated with PZA r (93.5% of cases). We confirmed a reduced but still present PZase activity for some of these variants as a development of faint color during the enzymatic assay. Whereas Leu172Pro was found to be associated with homoplasy, for other substitutions, the number of cases was too low to consider convergent evolution in different lineages.
Mutations with an unclear role in conferring PZA r . Five genetic variants (21 cases, category D) were found in both PZA r and PZA s isolates but at a proportion less than 70% in PZA r strains. Two genetic variants (15 cases) showed borderline behavior in terms of structure/free energy variation and enzyme activity. Homoplasy was found for the Val139Ala mutation, thus suggesting a putative role in phenotypic resistance or at least in increasing the MIC. Pro62Arg, Asp63Ala, and Ser65Pro substitutions (6 cases) represent another group of mutations belonging to this ambiguous category. Further characterization of these mutations is needed to better understand their correlation with the PZA phenotype.
Mutations not involved in phenotypic resistance. Twentyseven genetic variants were not associated with PZA r according to our classification. Eighteen mutations (163 cases, category C) were most frequently associated with PZA s (91.4% of cases). It should be noted that the Val21Ala mutation was also found associated with other mutations in category A responsible for PZA r / PZase negativity. Interestingly, all these mutations were found to be associated with single lineages; thus, no homoplasy was observed. Further characterization of these mutations is needed to better understand their role (if any) in PZA susceptibility. The remaining genetic variants (27 cases, category B) did not affect the amino acid sequence of the PZase enzyme. We observed two silent mutations: TCC65TCT (Ser65Ser), GCG38GCC (Ala38Ala). The Ser65Ser silent mutation was found associated with the Delhi/CAS lineage. In some cases, sequencing of the upstream region of pncA allowed the identification of a deletion at position Ϫ125 or an insertion at nucleotide Ϫ3; however, isolates harboring these genetic variants were found associated with both phenotypic resistance and susceptibility. According to these data, and supported by the lack of homoplasy for these mutations, the indels detected do not represent a marker for PZA r .
A total of 1,062 clinical isolates (1,062/1,950 [55.4%]) showed a WT sequence for the PZase enzyme (included in category B), and the sequence was associated with PZA s in more than 80% of cases. Enzymatic assay results were not available for all: 17 isolates (out of 138 tested; 12.3%) gave a negative PZase enzymatic activity, indicating that a WT PZase does not exclude phenotypic resistance a priori.
DISCUSSION
PZA DST is crucial for successful management of patients with susceptible and drug-resistant TB, especially with MDR TB. Furthermore, future shorter regimens for both drug-resistant and drug-susceptible TB will include PZA as a key drug for achieving both sterilization and prevention of the development of drug resistance to new drugs (17, 18) . Thus, reliable PZA r data for clinical isolates are crucial for guiding the clinical management of patients. Phenotypic tests, however, have a long turnaround time, are expensive, and are considered poorly reliable. As a consequence, the design of a molecular test for predicting PZA r is a priority. The development of a rapid molecular PZA DST is hampered by the diverse nature of resistance-associated mutations mainly scattered over the full length of the pncA gene, and by the fact that the impact of individual mutations has not been systematically investigated (4, 12) . Therefore, we performed a large-scale study linking pncA sequence diversity with phenotypic, structural biology and population biology data to develop the first encyclopedia of pncA sequence variations linked to either a PZA r or PZA s phenotype. This is likely to pave the way for application of new genome-based sequencing technologies for predicting PZA r , allowing for personalized treatment algorithms.
Strikingly, nearly 85% of the genetic variants identified in the pncA gene were associated with phenotypic resistance to PZA and were classified as "high-confidence" PZA resistance mutations. All in-frame and frameshift indel mutations within the coding region were included in this group. We found that nearly 90% of observed mutations are associated with protein structural destabilization that causes loss of enzymatic activity. Equally importantly, we described 27 mutations most likely not involved in PZA resistance that should be "filtered out" in future molecular tests and labeled as not "clinically relevant" (Fig. 4) . Only five mutations cannot be classified by our approach and remain without clear association with a resistance or susceptible phenotype. These mutations need further validation for association with PZA r and/or with a specific genetic background by an allelic exchange procedure as performed for other drugs (19) .
Discrepancies between molecular and phenotypic DST are confusing for clinicians managing patients; 180 isolates investigated here showed discrepant results between phenotypic and genotypic tests (WT pncA gene sequence and resistance by Bactec MGIT 960 DST). It has been reported that the Bactec MGIT 960 mycobacterial detection system may overestimate resistance even in the best laboratory settings (due to changes in the medium pH and/or variability in the inoculum size). Alternatively, a different mechanism of resistance, such as mutations in rpsA, could also be hypothesized for a few cases, although these were not clearly confirmed in clinical isolates (data not shown) (20) (21) (22) (23) . In Fig. S1 in the supplemental material, we modeled the impact of these "discrepant cases" in different hypothetical diagnostic scenarios to provide worst and best performances of pncA sequencing-based assay as follows. If all 180 cases were truly susceptible, the diagnostic accuracy of a molecular test for PZA based on sequence would be 98.77% (95% confidence interval [95% CI], 98.18 to 99.17%) (Fig. S1C ) in the range of the rifampin and isoniazid test results (11) . If the 180 cases were truly PZA r strains (wrongly predicted as PZA s by pncA gene sequence), the diagnostic accuracy of pncA sequencing in detecting PZA r would be 89.54% (95% CI, 89.21 to 90.82%), in the range of isoniazid resistance (Fig. S1B ) (11) .
Based on our findings, any future molecular test for PZA resistance should be able not only to detect the absence of the wild-type sequence but also to identify the specific SNPs. We found, indeed, a relevant number (10%) of mutations previously not reported as associated with drug resistance (DR) and the degree of variability in terms of indel mutations. In addition, we found mutations not associated with DR, including the previously reported lineagespecific genetic variants (e.g., TCC65TCT in Delhi/CAS) (14) . Ac-cordingly, only an assay with the capacity to provide in-depth sequence information could comply with the minimal requirements for a new molecular PZA r test. Fully automated, low-cost medium-density arrays and user-friendly whole-gene/wholegenome sequencing-based approaches will become a reality in the very near future and will be the most suitable assays to fulfill this task. In particular, new next-generation sequencing (NGS)-based diagnostics could represent innovative tools to reduce false PZA r cases and to improve safe and fast detection of drug resistances by molecular DST (24) . Our work has generated the minimum sets of mutations that should be included in any molecular test for PZA and provide a start point for a pncA genetic variation encyclopedia needed for the valid interpretation of data generated by massive sequencing approaches.
An additional aspect that is highlighted by our study is the great advantage in sharing large data sets generated by several groups. The establishment of a common database combining data from clinical isolates collected in a large number of settings was crucial to improve our understanding the role of pncA gene mutations in determining the PZA susceptibility phenotype of M. tuberculosis. The high number of samples providing sufficient reiteration of less frequent mutations together with the inclusion of different parameters (phenotype, genotype, enzymatic activity, structure, and free energy analyses) in a decision tree allowed us to define specific operational categories of mutations relevant from a clinical point of view. This enabled us to build a user-friendly diagnostic algorithm through the classification of specific SNPs in a shared database collecting more-complex information. These large shared databases of mutations involved in drug resistance could contribute to a better understanding of molecular mechanisms of resistance, improved molecular diagnostics, new diagnostic algorithms, and better public health control of drugsensitive and drug-resistant TB.
MATERIALS AND METHODS
Strain selection. Strains were made available by six TB National/Supranational Reference and partner laboratories within the TB-PANNET Consortium to provide wide coverage for most of the lineages observed for the M. tuberculosis complex. Strains were tested for PZA susceptibility and included in the study regardless of testing for other antitubercular drugs. PZA drug susceptibility testing (DST) was performed by using a Bactec MGIT 960 mycobacterial detection system and MGIT 960 PZA kits (BD, Franklin Lakes, NJ, USA) according to the manufacturer's instructions. A total of 1,950 clinical isolates were incorporated in the database. Whenever available, genotyping information (spoligotyping and/or mycobacterial interspersed repetitive-unitϪvariable-number tandem-repeat [MIRU-VNTR] typing [25] ) were collected. The MIRU-VNTRplus web tool (26, 27) was used to define lineage information (similarity search settings for identification: 0.17; distance measure for MIRU-VNTR: categorical, weighting 1; distance measure for spoligotyping: categorical, weighting 1).
pncA gene sequencing. DNA was extracted as described elsewhere (28) . The pncA gene (Rv2043c, NCBI gene identifier [ID] 888260), including the proximal promoter region, was amplified. On a subset of samples, the distal promoter region (Ͼ100 bp upstream of the start codon) was also included in the amplified region according to the protocol described in reference 29. Amplicons were sequenced with an automated DNA sequencer. The pncA gene sequence of isolates from Samara, Russian Federation, was determined from whole-genome sequencing data as previously described (15) . Mutations in the pncA gene were identified by comparison with the wild-type M. tuberculosis H37Rv pncA gene sequence.
PZase assay. PZase activity was evaluated as described by Singh et al. (30) . Briefly, a Middlebrook 7H9 (BD, Franklin Lakes, NJ, USA) 1.5% agarose containing PZA (Sigma-Aldrich Corporation, Saint Louis, MO, USA) at a final concentration of 400 g/ml was prepared. Melted PZA agar was distributed in glass tubes by using an agarose base to obtain a semitransparent medium allowing the detection of a faint pink band against a white background. A heavy loopful of actively growing culture was carefully inoculated on the surface of the PZA agar medium and incubated at 37°C for 4 days. One milliliter of ferrous ammonium sulfate (1%) was added to each tube after incubation and observed for 4 h for the appearance of a pink band (positive) in the subsurface agar. PZA-resistant isolates of M. bovis (negative by the PZase test) were used as negative controls, and the PZA-susceptible strain M. tuberculosis H37Rv was used as a positive control. All isolates showing discrepant results (namely, pncA mutant and PZase positive or WT pncA and PZase negative) were retested at 4 and 10 days (31).
PZase structure. For each amino acid substitution, we performed an in silico analysis of the free energy variation associated with the specific mutation taking into account an acidic environmental pH (6.0), very close to the one required for PZA activity. The crystal structure of the PZase enzyme determined to 2.2-Å resolution (PDB code 3PL1) (32) was used in conjunction with the program FoldX (33). Mean free energy variation was calculated for triplicates of predicted structures, and based on statistical analysis, a free energy variation greater than 2 kJ/mol was considered to destabilize the enzyme. Frameshifts and mutations affecting the promoter region were not considered. Free energy variation was then integrated with a visual structural analysis in order to identify substitutions tolerated by the free energy term but detrimental for the specific activity of the enzyme.
Statistical analysis. For understanding the significance of each mutation, we predicted the DST by fitting a conditional inference tree model considering results of sequencing, activity, and the combination of structure and energy analyses as predictors. In the model, we applied recursive partitioning based on conditional permutation tests. Furthermore, at each step, P values were adjusted for multiplicity by the procedure of Benjamini and Yekutiely (34) . The majority of recursive partitioning algorithms introduced since 1963 (35), such as CHAID and CART, yield trees with too many branches and can also fail to pursue branches which can add significantly to the overall fit. This leads to potential drawbacks: overfitting and a selection bias toward covariates with many possible splits or missing values (36, 37) .
This approach is able to address missing data, since it uses surrogate splits to determine the daughter node where the observations with missing values in the primary split variable are sent (for further details, see references 38 and 39). As output of the model, given an isolate's profile, a conditional probability of being PZA resistant is given. As a general rule, adjusted P values of less than 0.05 were considered significant. In the model, we applied recursive partitioning based on conditional permutation tests. In fact, when splitting, the use of the conditional distribution of the statistics ensures an unbiased selection of the covariates. This statistical approach prevented overfitting and overgrown trees, and no further pruning or cross-validation was needed.
Further details on the rationale used for the analysis is available in the supplemental material.
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